Stealth BioTherapeutics investigates SBT-272 to treat mitochondrial dysfunction in ALS
SBT-272, in the pipeline at Stealth BioTherapeutics, is a new peptidomimetic being investigated as a potential therapy for...
Stealth BioTherapeutics investigates SBT-272 to treat mitochondrial dysfunction in ALS
FDA approves oral edavarone to treat adults living with ALS
Sayuri Miyamoto to present a poster at the Paris Redox 2022 World Conference
Cornerstone for ALS Researchers
Research notes from Dr. Miyamoto
Welcome Dr. Anthony Akkari
Dr. Susanne Petri Joins NDR Scientific Group
NDR funds novel work in ALS research
Mesocyte Therapeutics puts ASC secretome therapy into the ALS patient pipeline
Bringing a treatment closer to patients
NDR awards $1.54 M drug development contract to WuXi App Tec
Student Grant Awarded to Rodrigo Santiago Lima